<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252420</url>
  </required_header>
  <id_info>
    <org_study_id>DDVTANZ</org_study_id>
    <nct_id>NCT01252420</nct_id>
  </id_info>
  <brief_title>Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis</brief_title>
  <acronym>TWISTER</acronym>
  <official_title>Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Health, Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Health, Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Adelaide Hospital, Adelaide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prince of Wales Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christchurch Hospital, NZ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Hospital, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Middlemore Hospital, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a limited duration of treatment (two weeks
      of low molecular weight treatment) is a safe and effective treatment for distal deep vein
      thrombosis of the lower limb.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50% of symptomatic episodes of deep vein thrombosis (DVT) will be confined to
      the calf veins (distal DVT). The proportion of distal DVT that propagate to the proximal
      veins, increasing the risk of pulmonary embolism, is not known. The best treatment of
      isolated distal DVT is therefore controversial and options include no treatment, follow-up
      scanning and treatment of only those patients with thrombus propagating to proximal veins,
      and full anticoagulation for periods ranging from 2 weeks to 3 months.

      There is good evidence that the 3-month thromboembolic risk in patients with a negative CUS
      that is limited to the proximal veins is low, in the order of 1%. Previous studies have
      demonstrated that patients treated with a short period of anticoagulation (4-6 weeks) have a
      low risk of developing recurrent DVT or PE. In addition, the specificity of CUS for distal
      DVT is lower than that for proximal DVT, increasing the proportion of false positive
      findings, making it likely that a proportion of patients diagnosed with distal DVT are
      treated unnecessarily, with the attendant risks of major and fatal haemorrhage.

      The need for anticoagulation of patients with distal DVT to prevent recurrent DVT is
      therefore uncertain, however a survey of current practice suggested that most patients with
      this condition currently receive antithrombotic therapy. The impact of anticoagulation on
      initial patient symptoms, and the subsequent risk of the post-thrombotic syndrome are also
      unclear, and may be a possible alternative justification for antithrombotic therapy.

      In this proposed multicentre, prospective, cohort study, we plan to determine if a shorter
      duration of anticoagulation (minimum 2 weeks) is a safe and effective treatment for isolated
      distal vein thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic recurrence of venous thrombosis (DVT, non fatal and fatal pulmonary embolism) within 3 months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic proximal thrombus extension at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of symptom resolution and the proportion of patients with complete resolution at two weeks.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time course of symptom resolution including time to complete resolution of symptoms, and the proportion of patients with complete resolution at two weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-thrombotic syndrome</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of recurrent or progressive DVT or new PE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>1.5mg/kg daily for 2 weeks</description>
    <other_name>Clexane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or older with acute symptomatic provoked or unprovoked distal
             vein thrombosis (axial or muscular veins but not involving trifurcation or distal
             popliteal vein)

          -  Absence of symptomatic pulmonary embolism

        Exclusion Criteria:

          -  DVT involving trifurcation or more proximal leg veins on imaging

          -  Prior DVT

          -  Active malignancy ie present at time of diagnosis, or on treatment, or treatment
             completed within 3 months

          -  Ongoing risk factors for propagation e.g. immobility (&gt;50% of day in bed or ≥72
             hours), plaster cast or non-weight bearing

          -  Other indication for therapeutic anticoagulation (e.g. AF)

          -  Active gastro-oesophageal ulceration or bleeding

          -  Other high risk for bleeding (e.g. recent neurosurgery, vascular retinopathy,
             coagulopathy)

          -  Platelet count &lt;80 x 109/L

          -  Renal impairment (CrCl &lt;30ml/min) • Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huyen Tran, MBBs(Hons), MClin Epidem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Brighton, MBBs, MD</last_name>
      <phone>+61293829013</phone>
      <email>Tim.Brighton@SESIAHS.HEALTH.NSW.GOV.AU</email>
    </contact>
    <investigator>
      <last_name>Tim Brighton, MBBs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon McRae, MBBs, BMedSci</last_name>
      <phone>+61 448882279</phone>
    </contact>
    <investigator>
      <last_name>Simon McRae, MBBs, BMedSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre, Southern Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Merriman, MBChB</last_name>
      <phone>+61 450011998</phone>
      <email>eileen.merriman@southernhealth.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Huyen Tran, MBBS, BClinEpi</last_name>
      <phone>+61 408780785</phone>
      <email>huyen.tran@southernhealth.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Huyen Tran, MBBs, MClinEp</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eileen Merriman, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjeev Chunilal, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Smith, MBChB</last_name>
      <phone>+64 3 3640640</phone>
      <email>mark.smith@cdhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Mark Smith, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>December 3, 2010</last_update_submitted>
  <last_update_submitted_qc>December 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Huyen Tran</name_title>
    <organization>Monash Medical Centre, Southern Health</organization>
  </responsible_party>
  <keyword>Distal Vein Thrombosis</keyword>
  <keyword>Proximal Vein Thrombosis</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Post-thrombotic syndrome</keyword>
  <keyword>Limited duration treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

